Septerna Emerges With $100m To Target Undruggable GPCRs
Start-Up Pairs Structural Insights With Computational Tools
Executive Summary
Septerna’s platform purifies G-coupled protein receptors (GPCR) to identify new drug targeting sites and then uses technologies such as machine learning to find novel compounds against hard-to-reach GPCRs.
You may also be interested in...
Finance Watch: Q2 Saw Fewer, But Larger, Venture Capital Deals
Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.